- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT02637154
Motivational Interview in Adolescents With Poorly Controlled Type 1 Diabetes
The Effect of Motivational Interview and Intensive Education on HbA1C Values and Glucose Variability in Adolescents With Poorly Controlled Type 1 Diabetes
This study investigates the effect of motivational interviewing and intensive education on HbA1c values and glucose variability in poorly controlled adolescent T1D patients.
In the present study motivational interviewing (MI) will be integrated to clinicians' daily practice, as a part of normal clinical visit. In this randomized, controlled trial hypothesis is, that applying motivational interviewing during regular clinical visits results in better acceptance and subsequently enhanced metabolic control in adolescents with poorly controlled type 1 diabetes.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
Background Type 1 diabetes (T1D) patients with optimal glycemic control suffer markedly less from long term diabetic complications than those with poor control. Increased glycohemoglobin (HbA1C) levels predict the complication risk. The development of diabetic complications seems to accelerate during puberty, and poor metabolic control during adolescence or young adulthood markedly increases the incidence of micro- or macrovascular complications during subsequent years. On the other hand, intensive treatment during adolescence has been reported to reduce the risk of microvascular complications, even if the control later on becomes poorer. This implicates that interventions targeting at improved glycemic control during adolescence probably have sustained beneficial effects on the overall morbidity in patients T1D.
The glycemic control of Finnish adolescents with T1D is poor. Insulin resistance and impaired metabolic control are common problems. Treatment of the disease during puberty can be complicated and particularly treatment adherence often declines in youth. Inexpensive and easily adoptable methods for clinicians are needed to overcome treatment problems faced with adolescent patients.
At present, there are no generally recommended approaches for clinicians to apply in order to motivate adolescents with poor glycemic control towards better treatment adherence. To this end, motivational interviewing (MI) has been used to an increasing degree in health care professionals in the treatment of variety of disorders and behavioral problems, such as alcohol and drug problems, gambling, and cardiovascular diseases. Motivational interviewing is a counseling approach designed to facilitate intrinsic motivation in the patient to change behavior. Significant body of evidence supports the view that MI improves commitment to care when added to other treatment. However, only a few studies have evaluated MI in the treatment of adolescent diabetes patients, with outcomes ranging from substantial benefit to neutral. MI is a promising approach for the treatment adolescent type 1 diabetics but there is a clear demand for methodologically solid studies.
Aims The aim of the present study is to investigate the effect of motivational interviewing and intensive education on HbA1c values and glucose variability in poorly controlled adolescent T1D patients. Secondarily, it will be investigated whether improved glycemic control is associated with improvements in vascular parameters, metabolic markers, markers of bone health and health related quality of life.
Hypothesis In the present study motivational interviewing (MI) will be integrated to clinicians' daily practice, as a part of normal clinical visit. In this randomized, controlled trial hypothesis is, that applying motivational interviewing during regular clinical visits results in better acceptance and subsequently enhanced metabolic control in adolescents with poorly controlled type 1 diabetes.
Study protocol All physicians participating in the study are trained to use standardized educational (SE) material. In addition half of the physicians are randomized to motivational interview (MI) group. They are trained by professor Martti Tuomisto's group to use MI in a one day workshop with refresher practical rehearsal course prior to study start. To secure that MI is sufficiently applied, the physician/patient discussions will be monitored by the Tuomisto group. All researchers randomized to the MI group will receive continuous feedback from the Tuomisto group on their performance (i.e. level of applying MI) and if needed re-trained for MI.
Patients with Hba1c > 75 mmol/mol are identified from hospital records, and are considered eligible for the current study. The patients willing to participate are randomized either to MI plus SE or SE group.
Study Protocol Every visit includes a physical examination (including evaluation of the stage of puberty and testis volume at the start and at 12 months), measurement of height, weight, growth velocity, body mass index (BMI), blood pressure and waist circumference, usage of SE material, and in the MI group usage of MI during the patient visit. The intervention in the MI group consists of a MI type of introduction at the beginning of each patient visit, and applying MI principles and procedures on each educational item discussed during the patient visit. Adherence to MI intervention protocols will be checked using recorded samples of therapy interactions. HbA1c levels are also measured in every visit.
Six days blinded continuous glucose monitoring will be performed at baseline and during the follow-up (0, 6 and 12 months).
Fasting venous blood samples are obtained at baseline and at 12 months. Investigators will evaluate health related quality of life (QoL) in study participants at baseline, and at completion of the study.
Dual- energy x-absorptiometry (DXA) is performed at baseline and at 12 months. Vascular assessments will be performed at baseline and at study completion.
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
-
Espoo, Finsko, 00029
- Helsinki University Central Hospital, Pediatric Diabetes Unit Espoo
-
Helsinki, Finsko, 00029
- Helsinki University Central Hospital, Pediatric Endocrinology Unit
-
Oulu, Finsko
- Oulu University Hospital, Pediatric Endocrinology Unit
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- the diagnosis of type 1 diabetes with at least 2 years duration and HbA1c > 75 mmol/mol on two consecutive visits, age 12-15.9 years and pubertal (Tanner) stage 2 or more at inclusion
Exclusion Criteria:
- celiac disease with poor control; diagnosis of psychiatric disease; and other chronic disease requiring per oral glucocorticoid treatment
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Podpůrná péče
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Singl
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Aktivní komparátor: Motivational Interviewing
With 30 patients Motivational Interviewing method will be used during each visit
|
Motivational Interviewing method
|
|
Aktivní komparátor: Standard Education
With 30 patients Standard Education material will be used during each visit
|
Standard Education material will be used
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in HbA1C values (mmol/mol)
Časové okno: 12 months
|
HbA1c levels (mmol/mol) are measured in every visit (AfinionTM).
|
12 months
|
|
Change in glycaemic variability
Časové okno: 12 months
|
Six days blinded continuous glucose monitoring (CGM) (iPro, Medtronic) will be performed at baseline and during the follow-up.
Blinded CGM curves (0 and 12mo) will be analyzed to study effect on glycemic variability.
Standard deviation (SD) of blood glucose values and mean amplitude of glycemic excursions (MAGE) will be used as parameters to define glycemic variability.
|
12 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Influence of changes in markers of vascular health (IMT)
Časové okno: 12 months
|
The association between glycemic control and vascular wall morphology is assessed by imaging of the carotid, femoral, brachial and radial artery intima media thickness (IMT as millimeters - mm:s) with ultrasound.
Results will be compared to previously established measurements from healthy children.
Vascular assessment will be performed at baseline and at study completion.
|
12 months
|
|
Influence of changes in markers of vascular health (PWV)
Časové okno: 12 months
|
The association between glycemic control and central and peripheral arterial thickness is assessed with pulse wave velocity (PWV - as meters / second - m/s) using applanation tonometry.
Results will be compared to previously established measurements from healthy children.
Vascular assessments will be performed at baseline and at study completion.
|
12 months
|
|
Influence of changes in bone mineral density (BMD)
Časové okno: 12 months
|
Dual- energy x-absorptiometry (DXA) is performed at baseline and at 12 months for analyses of BMD (total body less head, lumbar spine) and body composition, using the Hologic Discovery device (indicated as SD of Z-score).
|
12 months
|
|
Influence of changes in quality of life
Časové okno: 12 months
|
Health related quality of life (QoL) in study participants will be evaluated at baseline, and at completion of the study with the KINDL-R questionnaires
|
12 months
|
|
Influence of changes in markers of inflammation (IL-6 - pg/ml)
Časové okno: 12 months
|
Fasting venous blood samples are obtained at baseline and at 12 months for later analysis of serum inflammatory marker serum IL-6.
|
12 months
|
|
Influence of changes in markers of inflammation (high-sensitive-c-reactive-protein CRP - mg/l).
Časové okno: 12 months
|
Fasting venous blood samples are obtained at baseline and at 12 months for later analysis of serum inflammatory marker hs-CRP.
|
12 months
|
|
Influence of changes in insulin-like-growth-factor IGF-I levels
Časové okno: 12 months
|
Fasting venous blood samples are obtained at baseline and at 12 months for later analysis of serum insulin-like-growth-factor IGF-I (ng/ml) levels.
|
12 months
|
|
Influence of changes in markers of bone turnover (serum aminoterminal propeptide of type I collagen (PINP - ng/ml)).
Časové okno: 12 months
|
Fasting venous blood samples are obtained at baseline and at 12 months for later analysis of markers of bone turnover (PINP - ng/ml).
|
12 months
|
|
Influence of changes in vitamin D status (25-hydroxy-D) ng/ml
Časové okno: 12 months
|
Fasting venous blood samples are obtained at baseline and at 12 months for analysis of changes in vitamin D status.
|
12 months
|
|
Influence of changes in marker of bone turnover: osteocalcin (ng/ml)
Časové okno: 12 months
|
Fasting venous blood samples are obtained at baseline and at 12 months for analysis of changes in bone turnover marker osteocalcin.
|
12 months
|
|
Influence of changes in marker of bone turnover: aminoterminal telopeptide of type I collagen (INTP - ng/ml)
Časové okno: 12 months
|
Fasting venous blood samples are obtained at baseline and at 12 months for analysis of changes in bone turnover marker INTP.
|
12 months
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Mari Pulkkinen, MD PhD, Specialist in Pediatric Endocrinology
Publikace a užitečné odkazy
Obecné publikace
- Rubak S, Sandbaek A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract. 2005 Apr;55(513):305-12.
- Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970 Sep;19(9):644-55. doi: 10.2337/diab.19.9.644. No abstract available.
- Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group; Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, Orchard TJ. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med. 2009 Jul 27;169(14):1307-16. doi: 10.1001/archinternmed.2009.193.
- Bryden KS, Dunger DB, Mayou RA, Peveler RC, Neil HA. Poor prognosis of young adults with type 1 diabetes: a longitudinal study. Diabetes Care. 2003 Apr;26(4):1052-7. doi: 10.2337/diacare.26.4.1052.
- White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr. 2001 Dec;139(6):804-12. doi: 10.1067/mpd.2001.118887.
- Channon S, Smith VJ, Gregory JW. A pilot study of motivational interviewing in adolescents with diabetes. Arch Dis Child. 2003 Aug;88(8):680-3. doi: 10.1136/adc.88.8.680.
- Valerio G, del Puente A, Esposito-del Puente A, Buono P, Mozzillo E, Franzese A. The lumbar bone mineral density is affected by long-term poor metabolic control in adolescents with type 1 diabetes mellitus. Horm Res. 2002;58(6):266-72. doi: 10.1159/000066441.
- Sarkola T, Redington A, Keeley F, Bradley T, Jaeggi E. Transcutaneous very-high-resolution ultrasound to quantify arterial wall layers of muscular and elastic arteries: validation of a method. Atherosclerosis. 2010 Oct;212(2):516-23. doi: 10.1016/j.atherosclerosis.2010.06.043. Epub 2010 Jul 7.
- Pulkkinen MA, Tuomaala AK, Hero M, Gordin D, Sarkola T. Motivational Interview to improve vascular health in Adolescents with poorly controlled type 1 Diabetes (MIAD): a randomized controlled trial. BMJ Open Diabetes Res Care. 2020 Jul;8(1):e001216. doi: 10.1136/bmjdrc-2020-001216.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Očekávaný)
Dokončení studie (Očekávaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- MoHa
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Diabetes mellitus, typ 1
-
Children's Hospital Medical Center, CincinnatiZatím nenabíráme
-
Consun Pharmaceutical GroupNábor
-
Helen Keller Eye Research FoundationFive Lakes Clinical Research Consulting, LLCNáborSticklerův syndrom typu 2 | Sticklerův syndrom typu 1Spojené státy
-
Institute of Child HealthGreat Ormond Street Hospital for Children NHS Foundation TrustNáborSMA1Spojené království
-
Medstar Health Research InstituteLatham FundZatím nenabírámeDiabetes | Těhotenství | Diabetes (inzulín vyžadující, typ 1 nebo typ 2)
-
Laval UniversityZatím nenabíráme
-
University of BernDexCom, Inc.; DCB Research AG; mylife Diabetes Care AGNábor
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Nábor
-
Hoffmann-La RocheDokončenoDiabetes 2. typu, Diabetes 1. typuRakousko, Spojené království
-
PolTREG S.A.Medical Research Agency, Poland; Clinmark Clinical Research; Invicta Sp. z o.o.NáborDiabetes mellitus, typ 1 | Diabetes Mellitus, typ I | Pressymptomatický diabetes typu 1 (fáze 1)Polsko
Klinické studie na Motivational Interviewing
-
University of MichiganCenters for Disease Control and PreventionDokončenoGlaukomSpojené státy
-
Northwell HealthNational Institute on Alcohol Abuse and Alcoholism (NIAAA)DokončenoPití alkoholu | Alkoholismus | Poruchy související s alkoholem | Poruchy užívání alkoholu | Zneužití alkoholuSpojené státy
-
University of Massachusetts, WorcesterEunice Kennedy Shriver National Institute of Child Health and Human Development... a další spolupracovníciAktivní, ne náborPreexpoziční profylaxeThajsko
-
Wayne State UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Dokončeno
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute of Mental Health...Dokončeno
-
University of MichiganNational Institute on Drug Abuse (NIDA)DokončenoZneužívání drogSpojené státy
-
Emory UniversityDokončeno
-
University of MichiganNational Institute on Alcohol Abuse and Alcoholism (NIAAA)DokončenoZneužívání alkoholuSpojené státy
-
University of MichiganNational Institute of Nursing Research (NINR)Nábor
-
University of California, Los AngelesBoston University; University of California, San Diego; Providence Health & ServicesDokončenoChování při pití | Nadměrné pití | Těžké pitíSpojené státy